Osteoporosis
Across
- 2. T scores between -1.0 and -2.5
- 3. a standard measurement for measuring bone density
- 4. thyroid risk factor
- 6. Repeat measures of bone density every 1-2 years after starting _______.
- 9. Daily requirement of 1,000 – 1,500 mg in divided doses with meals
- 14. Lab measurement for secondary causes of osteoporosis (parathyroid hormone, TSH, 25-hydroxyvitamin D
- 15. Alendronate, Risedronate, ibandroante
- 20. Best locations for measuring bone density
- 21. Sensitive screening test for above
- 23. The lifetime risk of a hip fracture in a woman with T-score of 0
- 25. Related to the GI tract
- 26. SERM FDA approved for prevention and treatment of osteoporosis
- 27. subcutaneous injection daily for osteoporosis
- 29. Severe side effect of medications above, higher in patients with cancer receiving IV version
- 33. Medication risk factor
- 36. lab evaluation for secondary osteoporosis (calcium, phosphorus, albumin, alkaline phosphatase
- 37. 50% of women with_____ fractures are unable to walk independently after their fracture heals.
Down
- 1. Prolonged premenopausal ______ (risk factor)
- 5. 800 _______ of vitamin D daily
- 7. 50% of _______ older than 50 years will experience an osteoporotic fracture
- 8. Activity resulting in a 5-10% reduction in bone density
- 10. a measurement for bone density compared to people of the same age
- 11. ________ less than 127lbs (risk factor)
- 12. Exercise important for increasing bone mineral density
- 13. offered to women without preexisting fractures and T-score <-2.0, women with T-score -1.5 and another clinical risk factor, and women with prior osteoporotic fractures
- 16. A monoclonal antibody against _____, denosumab (Prolia)
- 17. Women older than ________ should have a bone mineral density test.
- 18. IV medication given yearly
- 19. Chronic daily use above 7.5mg prednisone or equivalent associated with bone loss
- 22. duel-energy x-ray ________
- 24. Risk factor for osteoporosis
- 28. ___________ history of a hip fracture (risk factor)
- 30. A disease of the bone characterized by a predisposition to low-trauma fracture caused by low bone mass and disordered microarchitecture.
- 31. 200 IU daily nasal spray for treatment of osteoporosis
- 32. disordered mineralization of newly formed bone protein matrix, associated with low serum phosphate and elevated serum alkaline phosphatase
- 34. Disease associated with chronic malabsorption occurring in ~1% Caucasian women
- 35. Deficiency associated with hypophosphatemia and hypocalcemia